CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

European Journal of Immunology - Tập 34 Số 2 - Trang 336-344 - 2004
François Ghiringhelli1,2, Nicolas Larmonier1, E. Schmitt1, Arnaud Parcellier1, Dominique Cathelin1, Carmen Garrido1, Jean‐Yves Blay1, Éric Solary1, Bernard Bonnotte1, François Martin1
1INSERM U517, Faculty of Medicine, Dijon, France
2The first two authors contributed equally to this study.

Tóm tắt

AbstractWe investigated the mechanisms of immune tolerance raised by tumors by comparing immunogenic and tolerogenic tumor cell clones isolated from a rat colon carcinoma. When injected into syngeneichosts, the immunogenic REGb cells yield tumors that are rejected, while the tolerogenic PROb cells yield progressive tumors and inhibit the regression of REGb tumors. We show here that PROb tumor volume is correlated with an expansion of CD4+CD25+ regulatory T lymphocytes in lymphoid tissues. These cells delay in vivo the rejection of REGb tumors and inhibit in vitro T cell‐mediated immune responses against REGb cells through a mechanism that requires cell contact between effector and regulatory T cells and involves TGF‐β. While total T cells fromPROb tumor‐bearing rats yield no apparent anti‐tumor immune response, depletion of CD25+ T cells restores this reactivity. A single administration of cyclophosphamide depletes CD4+CD25+ T cells in PROb tumor‐bearing animals, delays the growth of PROb tumors, and cures rats bearing established PROb tumors when followed by an immunotherapy which has no curative effect when administered alone. These results demonstrate the role of CD4+CD25+ regulatory T cells in tumor‐induced immune tolerance and the interest of regulatory T cell depletion to sensitize established tumors to immunotherapy.

Từ khóa


Tài liệu tham khảo

10.1073/pnas.95.3.1178

10.1084/jem.151.1.69

10.1038/86297

10.1038/ni0302-215

Sakaguchi S., 1995, Immunologic self tolerance maintained by activated T cells expressing IL2 receptor α chain (CD25). Breakdown of a single mechanism of self‐tolerance causes various autoimmune diseases., J. Immunol., 155, 1151, 10.4049/jimmunol.155.3.1151

10.4049/jimmunol.165.6.3105

10.1084/jem.193.11.1285

10.1038/nri821

10.1034/j.1600-065X.2001.1820102.x

Shimizu J., 1999, Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity., J. Immunol., 163, 5211, 10.4049/jimmunol.163.10.5211

Onizuka S., 1999, Tumor rejection by in vivo administration of anti‐CD25 (interleukin‐2 receptor alpha) monoclonal antibody., Cancer Res, 59, 3128

10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1

10.1084/jem.194.6.823

Steitz J., 2001, Depletion of CD25+CD4+ T cells and treatment with tyrosinase‐related protein 2‐transduced dendritic cells enhance the interferon‐α‐induced, CD8+ T cell‐dependent immune defense of B16 melanoma., Cancer Res., 61, 8643

10.1002/ijc.2910420616

10.4049/jimmunol.167.9.5077

10.4049/jimmunol.168.9.4272

10.4049/jimmunol.169.5.2756

Wolf A. M., 2003, Increase in regulatory T cells in the peripheral blood of cancer patients., Clin. Cancer Res., 9, 606

10.1002/eji.200323570

10.1016/S1359-6101(03)00003-0

Bonnotte B., 1998, Bcl‐2‐mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicityof spontaneously regressive tumors., J. Immunol., 161, 1433, 10.4049/jimmunol.161.3.1433

10.1038/249654a0

Berd D., 1988, Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor‐inducer T cells., Cancer Res., 48, 1671

10.1084/jem.155.4.1063

10.1016/S0140-6736(98)07186-4

10.1002/(SICI)1097-0215(19970807)72:4<619::AID-IJC12>3.0.CO;2-6

Thông tin
Thông tin xuất bản

European Journal of Immunology

Tập 34 Số 2

336-344

Thông tin tác giả